0001133416-24-000050.txt : 20240805 0001133416-24-000050.hdr.sgml : 20240805 20240805083845 ACCESSION NUMBER: 0001133416-24-000050 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240802 FILED AS OF DATE: 20240805 DATE AS OF CHANGE: 20240805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jamil Khurram CENTRAL INDEX KEY: 0002032345 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 241173222 MAIL ADDRESS: STREET 1: 31 DAVID DRIVE CITY: NEWTOWN STATE: PA ZIP: 18940 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 3 1 form3.xml X0206 3 2024-08-02 0 0001133416 GALECTIN THERAPEUTICS INC GALT 0002032345 Jamil Khurram 31 DAVID DRIVE NEWTOWN PA 18940 true Chief Medical Officer Common Stock Option (right to buy) 2.2 2034-03-11 Common Stock 150000 D Restricted Stock Unit 0 Common Stock 30000 D The Common Stock Options were granted to the Reporting Person by the Issuer in connection with his employment as vice president clinical development and medical director in March 2024 prior to his appointment as Chief Medical Officer by the Board of Directors. The options are exercisable in three equal traches on March 11, 2025, March 11, 2026, and March 11, 2027. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested. The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. Jack W. Callicutt, by power of attorney 2024-08-05 EX-24.1 2 poa_jamil.htm
POWER OF ATTORNEY
FOR SEC FILINGS ON FORMS ID, 3, 4, 5 AND 144
IN RESPECT OF SECURITIES OF
GALECTIN THERAPEUTICS INC.
 
The undersigned hereby constitutes and appoints each of Jack W. Callicutt and Joel Lewis as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution for him in his name and stead in any and all capacities, to sign and file for and on her behalf, in respect of any acquisition, disposition or other change in ownership of any Common Stock or derivative securities thereof of Galectin Therapeutics Inc. (the "Company"), the following:

(i)
any Form ID to be filed with the Securities and Exchange Commission (the "SEC");
(ii)
any Initial Statement of Beneficial Ownership of Securities on Form 3 to be filed with the SEC;

(iii)
any Statement of Changes of Beneficial Ownership of Securities on Form 4 to be filed with the SEC;

(iv)
any Annual Statement of Beneficial Ownership of Securities on Form 5 to be filed with the SEC;

(v)
any Notice of Proposed Sale of Securities on Form 144 to be filed with the SEC; and

(vi)
any and all agreements, certificates, receipts, or other documents in connection therewith. The undersigned hereby gives full power and authority to the attorney-in-fact to seek and obtain as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release such information to the undersigned and approves and ratifies any such release of information. The undersigned hereby grants unto such attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary in connection with such matters and hereby ratifies and confirms all that any such attorney-in-fact and agent or substitute may do or cause to be done by virtue hereof. The undersigned acknowledges that:

(i)
 neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), (ii) any liability of the undersigned for any failure to comply with such requirements or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

(ii)
this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.


IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney.
 

Date:  July 29, 2024     /s/ Khurram Jamil
                                      Khurram Jamil